Sponsors
Conference Info:
- Date: Thursday, July 12th, 2012
- Receptions: July 11th and 12th evening, 2012
- Location: Metropolitian Club, New York City
- Audience: Institutional investors, high net worth individual investors, family offices, business development executives throughout the US and Europe building and financing high growth medical technology, health care and life science companies.
- Date: Thursday, July 12th, 2012
Panels
July 12th – Health Information Panel
This panel will focus on the technological developments in healthcare provider-physician-patient communication. Commercial and professional technology is shifting toward cloud-based computing, but what does that mean for the medical industry, which is not yet in the final stages of going paperless? On the drug development side, it is estimated that 40 percent of clinical trials use paper; in hospitals and physician offices, doctors are just beginning to take advantage of the patient communication opportunities televisions and tablets have to offer. In the digital world, our culture has accessJuly 12th – Medical Devices Panel
The medical device space possesses two inherent qualities that investors value: stability, and disruptive technology. On the one hand, there is myriad framework for sales models, predictable revenue streams, international efforts, infrastructure and regulatory boundaries, as medical device companies can draw upon the practices of healthcare companies, consumer product companies and technology companies. On the other hand, it is one of the few spaces in which disruptive technology can have an immediate impact. Particularly intriguing is the trend to grow in non-healthcare fields and in the consJuly 12th – Biotechnology Panel
This session will provide an overview of the big developments in primary areas of biotechnology investing, including regenerative medicine, neurological disorders, vaccines and infectious diseases. This panel will also discuss which therapeutic areas of development will see most investment activity, viable financing alternatives for small public and private companies, current issues in clinical trial implementation, marketing strategy as well as how to best position your company for a strategic exit – as large pharma seeks to boost its pipeline by finding innovative new targets and compounds.July 12th – Oncology Panel
Despite the myriad of information and analysis on the subject of cancer treatment, there still remain several promising opportunities considered 'alternative' to the general public. Brachytherapy, for example, is an appealing emerging technology to investors, physicians and patients as a safer and more targeted alternative to chemotherapy. A common effective treatment for cervical, prostate, breast and skin cancer, brachytherapy (or radiotherapy) is being expanded to treat different cancers. Analyzing the success of radiotherapy treatment for various cancers, entities have thus begun to develoJuly 12th – Regenerative Medicine Panel
In the political arena, the issue of regenerative medicine and 'stem cells' is an emotive and volatile debate. In the medical field, however, there is less question as to the 'why', and instead, a focus on the 'how' and 'when'. The perfection and subsequent implementation of replacing damaged, lost or aging tissues and organs through replacement or autologous stimulation will have profound effects on the ceiling of modern medicine and treatment. The fields of chronic pain, organ and age-related disease, cancer and autoimmune disease may soon see a paradigm shift toward regenerative treatment,July 12th – Diagnostics Panel
As technology evolves, molecular and diagnostic (Dx) tests are becoming more convenient, quicker, cheaper and more available closer to or at the point of care (POC). The convergence between understanding the genome, developing biomarkers for certain diseases and technology is already accelerating the growth of (and interest in) this space. The ability to treat a patient faster and more effectively will cut out so much excess cost in the system. Drug companies are already teaming up with Dx companies to develop tests that look for biomarkers that the biopharma companies’ drug targets. So instea